Stocktoria
Allogene Therapeutics, Inc. ALLO
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2018-10-11
Allogene Therapeutics, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $22,000 | $95,000 | $156,000 | $114.1M |
| R&D expense | $150.2M | $192.3M | $242.9M | $256.4M | $220.2M |
| Operating income | -$209.3M | -$273.2M | -$327.7M | -$335.5M | -$180.2M |
| Income tax | $0 | $443,000 | $0 | $0 | $0 |
| Net income | -$190.9M | -$257.6M | -$327.3M | -$340.4M | -$182.1M |
| EPS (diluted) | $-0.87 | $-1.32 | $-2.09 | $-2.38 | $-1.34 |
| Operating cash flow | -$149.2M | -$200.3M | -$237.7M | -$220.5M | -$184.8M |
| Free cash flow | -$149.6M | -$201.0M | -$239.2M | -$225.7M | -$206.3M |
| Cash & equivalents | $51.7M | $75.2M | $83.2M | $61.9M | $173.3M |
| Total assets | $415.9M | $548.7M | $642.8M | $821.6M | $1.0B |
| Total liabilities | $123.4M | $126.5M | $130.6M | $154.7M | $122.2M |
| Shareholders' equity | $292.5M | $422.2M | $512.2M | $666.9M | $925.2M |
Source: SEC EDGAR filings · CIK 0001737287 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.